摘要
乳腺癌是女性中最常见的癌症,全世界每年大约有50万人死于乳腺癌。在乳腺癌治疗的各种方法中,化疗主要用于分期i - iv期患者,单克隆抗体(mAb)治疗用于人类表皮生长因子受体2(HER2)的过度表达。整合肿瘤特异性由独特的mAbs和小分子药物的细胞毒性提供,抗体药物结合(ADCs)是一系列的智能化疗药物,最近在治疗许多癌症类型方面显示了巨大的前景。ADCs被设计成有选择性地攻击和杀死对正常组织毒性最小的癌细胞。青霉素 - 曲妥珠单抗是美国食品和药物管理局批准的用于HER2阳性乳腺癌的第一个也是唯一的ADC。随着t - dm1的成功,许多新的adc已经发展,它们的抗癌功效目前正在进行临床前或临床研究。ADCs的发展是一个快速发展的领域,这篇综述旨在总结过去5年(2011 - 2016年)针对乳腺癌的adc的最新进展。该综述强调了这些新开发的adc的组成和作用机制,并讨论了发展新adc治疗乳腺癌的当前挑战和未来发展方向。
关键词: 抗体药物偶联、乳腺癌、药物抗体比、单克隆抗体、靶向治疗、抗原。
Current Medicinal Chemistry
Title:Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment
Volume: 24 Issue: 23
关键词: 抗体药物偶联、乳腺癌、药物抗体比、单克隆抗体、靶向治疗、抗原。
摘要: Breast cancer is the most common cancer in women, with roughly half a million deaths per year worldwide. Among various approaches for breast cancer treatment, chemotherapy is predominantly used for patients at stages II-IV, and monoclonal antibody (mAb) therapy is used for patients with human epidermal growth factor receptor 2 (HER2) overexpression. Integrating the tumor specificity provided by unique mAbs and cytotoxicity of small molecule drugs, antibody-drug conjugates (ADCs) are a series of smart chemotherapeutics that have recently shown great promise in treating a number of cancer types. ADCs are designed to selectively attack and kill cancer cells with minimal toxicity to normal tissues. Ado-Trastuzumab emtansine (T-DM1) was the first and only ADC approved by the US Food and Drug Administration for HER2-positive breast cancer. Following the success of T-DM1, many novel ADCs have been developed, and their anticancer efficacies are currently undergoing preclinical or clinical investigation. The development of ADCs is a rapidly progressing field, and this review aims to summarize the most recent advances in ADCs targeting breast cancer over the past five years (2011-2016). The review highlights compositions and mechanisms of action of these newly developed ADCs and discusses current challenges and future directions of developing new ADCs for improved treatment of breast cancer.
Export Options
About this article
Cite this article as:
Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment, Current Medicinal Chemistry 2017; 24 (23) . https://dx.doi.org/10.2174/0929867324666170530092350
DOI https://dx.doi.org/10.2174/0929867324666170530092350 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Construction, Expression and Functional Characterization of the β-Lactamase with αv Integrin Ligands
Protein & Peptide Letters Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Menopause, A Universal Female Experience: Lessons from Mexico and Central America
Current Women`s Health Reviews Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Drug Targeting Strategies in Cancer Treatment: An Overview
Mini-Reviews in Medicinal Chemistry Anti-HIV Factors: Targeting Each Step of HIV’s Replication Cycle
Current HIV Research Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin
Current Pharmaceutical Design Antiglucocorticoids, Neurogenesis and Depression
Mini-Reviews in Medicinal Chemistry Targeting Bcl-2 in CLL
Current Medicinal Chemistry Bio-Distribution, Imaging Protocols and Diagnostic Accuracy of PET with Tracers of Lipogenesis in Imaging Prostate Cancer: a Comparison between 11C-Choline, 18FFluoroethylcholine and 18F-Methylcholine
Current Pharmaceutical Design HDACs and HDAC Inhibitors in Urothelial Carcinoma – Perspectives for an Antineoplastic Treatment
Current Medicinal Chemistry The Yin and Yang of CD4+ Regulatory T Cells in Autoimmunity and Cancer
Current Medicinal Chemistry Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Current Drug Targets Immunity to Tumour Antigens
Current Pharmaceutical Design Cancer Cell-derived Secretory Factors in Breast Cancer-associated Lung Metastasis: Their Mechanism and Future Prospects
Current Cancer Drug Targets The LPS-Pretreated MSCs Supply a Positive Microenvironment for Tumor Cell Proliferation and Clone Formation
Current Protein & Peptide Science Overexpression of RAD50 is the Marker of Poor Prognosis and Drug Resistance in Breast Cancer Patients
Current Cancer Drug Targets Protein Glycosylation as Marker of Melanoma Progression
Current Cancer Therapy Reviews MiR-492 as an Important Biomarker for Early Diagnosis and Targeted Treatment in Different Cancers
Current Cancer Therapy Reviews